Amgen’s psoriatic arthritis drug, brodalumab shows effectiveness after one year study

June 12, 2014 6:31 AM

13 0

Data from a mid-stage trial of Amgen’s Inc. drug brodalumab for psoriatic arthritis has shown effectiveness after one year of treatment with no new concerns about its safety.

AstraZeneca Plc, Amgen’s partner had presented data from a 3 month trial involving 168 patients which showed that the drug was more effective than placebo.

Read more

To category page